Agenda

12:00 PM EST

Approx. 50 minutes

Clinical Challenges in the Personalized Treatment of Advanced NSCLC

Presenting on August 12th, 2015

Mark Socinski, MD

University of Pittsburgh Cancer Institute

Panos Fidias, MD

Thoracic Oncology at University of Arizona Cancer Center at Dignity

 

Approx. 50 minutes

Understanding the Fundamentals: Clonal Heterogeneity of Multiple Myeloma, Implications for Treatment of Relapsed/refractory Disease

Presented on June 16th, 2015

Irene Ghobrial, MD

Harvard Medical School

Kenneth Anderson, MD

Harvard Medical School

 

Approx. 50 minutes

The Evolving Landscape of Treatment Options for Relapsed/Refractory MM

Presented on June 16th, 2015

Irene Ghobrial, MD

Harvard Medical School

Kenneth Anderson, MD

Harvard Medical School

 

Approx. 50 minutes

Testing for Genetic Mutations in Advanced NSCLC

Presented on May 19th, 2015

Mark Socinski, MD

University of Pittsburgh Cancer Institute

Panos Fidias, MD

Thoracic Oncology at University of Arizona Cancer Center at Dignity

 

Approx. 50 minutes

Selecting and Sequencing Therapies for Advanced Prostate Cancer

Presented on May 7th, 2015

Daniel J. George, MD

Duke University School of Medicine

Michael R. Harrison, MD

Duke University School of Medicine

 

Approx. 50 minutes

New Directions in the Management of Advanced Prostate Cancer

Presented on May 7th, 2015

Daniel J. George, MD

Duke University School of Medicine

Michael R. Harrison, MD

Duke University School of Medicine

 

Approx. 50 minutes

Personalizing the Management of Advanced Gastric Cancer

Presented on March 2nd, 2015

Kelsey Klute, MD

Weill Cornell Medical College

Manish A. Shah, MD

Weill Cornell Medical College

 

Approx. 50 minutes

Preventing and Treating Inhibitors in Patients with Hemophilia: Strategies for Success

Presented on March 6th, 2015

Lindsey A. Greene, MD

The Children's Hospital of Philadelphia

Patrick F. Fogarty, MD

Perelman School of Medicine, University of Pennsylvania

 

Approx. 50 minutes

New Directions in the Management of Mantle Cell Lymphoma

Presented on February 17th, 2015

James O. Armitage, MD

University of Nebraska Medical Center

Julie M. Vose, MD, MBA

University of Nebraska Medical Center

 

Approx. 50 minutes

Mantle Cell Lymphoma: Treatment Advances in the Front-line and Relapsed/Refractory Settings

Presented on June 16th, 2015

Ann LaCasce, MD

Harvard Medical School

Caron Jacobson, MD

Harvard Medical School

 

Approx. 50 minutes

Managing Ph+ Chronic Myelogenous Leukemia (CML) Resistant or Intolerant to Prior Therapy

Featuring Dr. George Howard

*This session is not eligible for AMA PRA Category 1 Credits TM

Sponsored by Pfizer, Inc.
Presented on September 19th, 2014

George Howard, MD

Oakland University William Beaumont School of Medicine

 

Approx. 50 minutes

A Patient-Focused Approach to the Evolving Treatment of Hemophilia

Featuring Dr. Michael D. Tarantino

*This session is not eligible for AMA PRA Category 1 Credits TM

Sponsored by Pfizer, Inc.
Presented October 2nd, 2014

Michael D. Tarantino, MD

University of Illinois College of Medicine Peoria, IL

 

Approx. 50 minutes

Assessing Survival: What's the Endpoint?

Featuring Drs. Linda T. Vahdat and Scott D. Christensen

*This session is not eligible for AMA PRA Category 1 Credits TM

Sponsored by Eisai Inc.
Presented on May 19th, 2015

Linda T. Vahdat, MD

Weill Cornell Medical College

Scott D. Christensen, MD

UC Davis Cancer Care Network

 

Approx. 50 minutes

Clinical Decision Making in Treating Patients With mCRPC Who Have Progressed on ADT

Featuring Dr. Judd W Moul

*This session is not eligible for AMA PRA Category 1 Credits TM

Sponsored by Janssen Biotech, Inc.
Presented on December 17th, 2014

 
OmedLive
Watch Connect online with thousands of your peers.
Connect Engage in real-time Q&A with top factuly.
Choose Learn about the latest treatment options.
Connect Earn AMA PRA
Category 1 Credits
™.